SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems

BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network.

The two new institutions, which collectively analyze millions of genetic samples annually, include one of the leading nonprofit, multi-region integrated healthcare systems in the U.S. and a top 10 U.S. health system laboratory. Together, these institutions will leverage the AI-native, cloud-based SOPHiA DDM^™ to analyze complex genomic data at scale.

By adopting SOPHiA DDM^™, the two institutions will initially launch genomic testing for up to 60,000 patients annually across the West Coast and Midwest, enabling faster diagnosis and more personalized care for individuals living with hereditary cancers and rare diseases.

Both health systems will utilize SOPHiA DDM™ for Enhanced Exome, an AI-driven analytics application that supports comprehensive full-exome analysis for over 20,000 genes while enabling the ability to dive deeper into clinically relevant regions. With these capabilities directly embedded into their laboratory workflows, the institutions aim to expedite testing turnaround times, streamline operational costs, and expand internal research and innovation initiatives.

John Carey, Managing Director, North America, SOPHiA GENETICS, said: "Partnering with two of the largest health systems in the U.S. underscores the growing need for AI-powered genomic solutions capable of addressing increasingly complex use cases that can scale without adding operational burden. Combining advanced bioinformatics, the collective knowledge of a global community, and streamlined workflows, our AI enables healthcare institutions to unlock deeper insights."

Going forward, this collaboration positions both organizations with a scalable foundation to support future expansion of AI-driven precision medicine. Each year, these organizations serve a combined population of nearly one million cancer and rare disorder patients nationwide.

SOPHiA GENETICS continues to strengthen its presence in the United States while supporting leading healthcare institutions across some of the most complex areas of precision medicine. The expansion in the region reinforces the company's mission to democratize data-driven medicine by equipping researchers and clinicians with AI-powered solutions that accelerate healthcare innovation and research.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com or connect on LinkedIn. 

About SOPHiA GENETICS

SOPHiA GENETICS (NASDAQ:SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. 

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to the company's management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company's filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company's expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-major-expansion-in-the-united-states-with-the-signing-of-two-major-integrated-health-systems-302683856.html

SOURCE SOPHiA GENETICS